M&A Deal Summary

MilliporeSigma Acquires MAST Platform

On April 5, 2022, MilliporeSigma acquired information technology company MAST Platform from Lonza

Acquisition Highlights
  • This is MilliporeSigma’s 1st transaction in the Information Technology sector.
  • This is MilliporeSigma’s 1st transaction in the United States.
  • This is MilliporeSigma’s 1st transaction in Oregon.

M&A Deal Summary
Date 2022-04-05
Target MAST Platform
Sector Information Technology
Buyer(s) MilliporeSigma
Sellers(s) Lonza
Deal Type Divestiture

Target

MAST Platform

Bend, Oregon, United States
The MAST® platform enables the gathering of more frequent samples and collection of real-time data, including product attributes in hours instead of weeks, compared to manual sampling. The average cell culture process can save more than 80 hours of labor generally required for sample collection, handling, and analysis. The MAST® platform is based in Bend, Oregon.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

MilliporeSigma

Burlington, Massachusetts, United States
Category Company
Sector Life Science
DESCRIPTION

MilliporeSigma is a provider of U.S. and Canada life science business of of Merck KGaA.

DEAL STATS #
Overall 1 of 2
Sector (Information Technology) 1 of 1
Type (Divestiture) 1 of 2
State (Oregon) 1 of 1
Country (United States) 1 of 2
Year (2022) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-05-22 Mirus Bio

Madison, Wisconsin, United States

Mirus Bio is a developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery. Mirus Bio's expertise in nucleic acid delivery gives life scientists the most advanced tools for gene expression, biotherapeutic protein production, virus manufacturing, and genome editing. Mirus Bio was founded in 1995 and is based in Madison, Wisconsin.

Buy $600M

Seller(S) 1

SELLER

Lonza

Basel, Switzerland
Category Company
Founded 1897
Sector Life Science
Employees18,000
Revenue 6.7B CHF (2023)
DESCRIPTION
Lonza plant located in Portsmouth, New Hampshire.
Lonza plant located in Portsmouth, New Hampshire.

Lonza is a global company that focuses on the life sciences sector, offering products and services for the pharmaceutical, biotech, and nutrition markets. Their portfolio spans across biopharmaceutical development and manufacturing, consumer health, nutrition, microbial control solutions, and custom manufacturing of specialty chemicals. Lonza was founded in 1897 and is based in Basel, Switzerland.

DEAL STATS #
Overall 4 of 4
Sector (Information Technology) 1 of 1
Type (Divestiture) 4 of 4
State (Oregon) 1 of 1
Country (United States) 2 of 2
Year (2022) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-08 Arxada

Basel, Switzerland

Arxada is a provider of specialty chemicals for microbial control solutions, used to eliminate or control harmful and unwanted micro-organisms. Arxada’s products are critical ingredients in disinfectants, preservatives, sanitisers, personal care products, as well as coatings and other industrial uses. Arxada was founded in 1897 and is based in Basel, Switzerland.

Sell Fr.4.2B
Mergr

Product

Company

Legal